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Abstract 
Violacein is bacteria pigment made several strain such as J.lividum, C.violaceum, Duganella 
sp., Pseudoduganella sp., Collimonas sp. which found various environment from glacial to subtropical 
climate. The usage of violacein in the bio-application in the field is diverse to block growth of several 
type of living organism: gram positive bacteria, fungus, virus, protozoa, nematodes, parasites and some 
cancer cell line like Hep2, KM12, MOLT-4. Because of this versatile application potent, needs of 
amount of violacein and its derivation will be increase near future. 
Nevertheless this positive application prediction, the production of violacein and its derivation 
is just beginning stage. The crude violacein contained violacein and its derivation specific productivity 
is reported 12.4mg/L∙h and its final concentration is 0.44g/L using C.violaceum natural violacein 
producing host. In recombinant strain violacein producing field, recent reported recombinant E. coli 
produce pure violacein 0.710g/L, however, specific productivity is 3.1mg/ L∙h. On the other hands 
violacein measurement method is not standardized, spectrophotometry is generally used for 
measurement violacein but extinction coefficient doesn’t have unity every study. Moreover purity of 
crude violacein is also questionable without HPLC analysis. Thus violacein production field need more 
study for enhance productivity and standardizing measurement of crude violacein. 
Characterization of violacein producing strain Pseudoduganella sp. NI28 found forest soil 
sample. P. sp. NI28 is similar to Psedoduganella violanceinigra YIM 31327 98.8% for 16s rRNA, 95.9% 
for gyrB, 88.8% for vioA. Even this similarity NI28 shown better crude violacein production tendency 
in NB media two Pseudoduganella strains shown significantly different production of crude violacein, 
NI28 produced 14mg/L but type strain produced under 0.1mg at 24 hours culture. Following HPLC 
analysis, NI28 crude violacein contain more than 95% violacein in the extracted violacein almost similar 
purity of commercial violacein (Sigma Aldrich. USA). Antibacterial effect of extracted violacein from 
NI28 shown 78%, 96% and 99.5% S. aureus population decrease in violacein concentration 15μM, 
30μM and 60μM. Co-culture of violacein producing strain with S. aureus was tested with NI28 and 
type strain in the NB media using violacein productivity difference, violacein producing is more helpful 
to compete co-culture condition to eliminate viability of S. aureus in the media.  
For enhance of production of violacein, E. coli GPT vio and E. coli GPT pCOM10vio 
transformed tryptophan over-producing E. coli was produced crude violacein in 37°C fermentation. 
GPT vio produce more 95% concentration of deoxyviolacein form HPLC analysis. The final 
concentration of deoxyviolacein form GPT vio is 584.8mg/L, specific productivity of 24 hours 
fermentation is 20.91mg/L∙h which was 1.65 fold high specific productivity compare than recent 
reported strain of deoxyviolacein productivity.   
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Chapter 1. Violacein: Properties and Production of a Versatile Bacterial Pigment 
 
1.1 Summary 
Violacein-producing bacteria, with their striking purple hues, have undoubtedly piqued the 
curiosity of scientists since their first discovery. The bisindole violacein is formed by the condensation 
of two tryptophan molecules through the action of five proteins. The genes required for its production, 
vioABCDE, and the regulatory mechanisms employed have been studied within a small number of 
violacein producing strains. As a compound, violacein is known to have diverse biological activities, 
including as an anticancer agent and as an antibiotic against Staphylococcus aureus and other Gram-
positive pathogens. Identifying the biological roles of this pigmented molecule is of particular interest, 
and understanding violacein’s function and mechanism of action has relevance to those unmasking any 
of its commercial or therapeutic benefits. Unfortunately, the production of violacein and its related 
derivatives is not easy and so various groups are also seeking to improve the fermentative yields of 
violacein through genetic engineering and synthetic biology. This review discusses the recent trends in 
the research and production of violacein by both natural and genetically modified bacterial strains. 
  
2 
  
 
 
1.2 Natural Violacein-Producing Strains and Their Locales are Quite Diverse 
As a bisindole, violacein (Figure 1.1) is produced by diverse genera of bacterial strains, 
including Collimonas1, Duganella2, Janthinobacterium3,4,5 , Microbulbifer sp.6 and 
Pseudoalteromonas7,8,9. As varied as these violacein-producers are phylogenetically, so is the locales 
from which they have been isolated. As shown in Table 1.1, these include quite a selection of environs 
as these bacteria have been found associated with the surfaces of sea sponges7 and the rhizosphere of 
olive groves10, and even within glaciers4,11,12. Perhaps the best known genera, however, is 
Chromobacter13,14, which includes the strain C. violaceum15.  
 
1.3 Violacein as an Indicator of Quorum Sensing 
In most of violacein-producing bacterial strains isolated from nature, this bisindole is a 
secondary metabolite that is associated with biofilm production5. Moreover, its production within C. 
violaceum and other strains is regulated by quorum-sensing mechanisms16. Because it is easy to 
visualize, violacein production by C. violaceum has become a useful indicator of quorum sensing 
molecules and their inhibitors17,18,19,20. 
Violacein, as a compound, however, is not limited to use only as an indicator. Secondary 
metabolites often serve functions other than the bacteria’s immediate needs in growth and propagation. 
Many of these molecules are biologically active, and some have toxic properties to competing species 
giving the bacteria a competitive advantage. Because of these activities, many secondary metabolites 
have been found to have pharmacological properties and, thus, are of interest for clinical use. In first 
half of this review, therefore, we will review some of the biological functions, clinical significance, and 
mechanisms of action of violacein. 
  
1.4 Violacein’s Function in Nature - Predator Defense? 
As noted above, violacein-producing bacteria encompass various genera and are found in all 
types of natural environments, from marine to freshwater and soil environments (Table 1.1). For this 
reason, it is rather difficult to pinpoint violacein’s main biological or ecological role. One possible 
commonality is that violacein producers are generally sessile bacteria that this makes them often more 
vulnerable to predation6. This presents the idea that violacein serves as some sort of defense mechanism 
for its producing strain or that it provides these sessile bacteria some competitive advantage. 
Consistent with this, violacein was shown to have antibacterial properties particularly towards 
Gram-positive bacterial strains21,22. One strain in particular that has received most of the recent attention  
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Figure 1.1. Structures of violacein, deoxyviolacein and oxyviolacein showing either the presence or 
lack of the hydroxyl groups. The structures were prepared using ChemDoodle 2D sketcher 
(http://web.chemdoodle.com/demos/sketcher). 
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Table 1.1. Some violacein-producing strains and the locales from which they were isolated. 
 
Strain Locale Reference 
 
Chromobacterium violaceum 
River 
Waste Water Treatment Plant 
14 
23 
Collimonas sp. Arctic Coastal Waters 1 
Duganella sp. Agricultural Soils (Olive) 10 
D. violaceinigra Forest Soils 24 
Janthinobacterium lividum Glacier 4 
J. svalbardensis Glacier 11 
Pseudoalteromonas sp. Deep Sea Waters (320 m) 25 
P. luteoviolacea Sea Sponge Surface 7 
 
 
Table 1.2. Eukaryotic organisms in which violacein was shown to produce negative effects. 
 
Type Organism Description Reference 
Fungi Batrachochytrium dendrobatidis Infects amphibians 26 
Protozoa Rhynchomonas nasuta Flagellate 6 
 Tetrahymena sp Ciliate 6 
 Acanthamoeba castellanii Amoeba 6 
 Leishmania amazonensis Causative agent of leishmaniasis 27 
 Plasmodium falciparum Causative agent of malaria in humans 28 
 Plasmodium chabaudi chabaudi Causative agent of malaria in mice 28 
Nematode Caenorhabditis elegans  29 
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is Staphylococcus aureus, in part due to its status as a multi-drug resistant pathogen22,30,31,32. Two studies 
showed crude violacein was capable of inhibiting S. aureus growth at concentrations between 5.7 and 
15mg/L, or approximately 17 to 43 µmol/L30,32. Violacein’s biological activity is not limited to 
prokaryotes, however, as it is also known to have negative effects on bacteriovorous protozoans and 
metazoans (Table 1.2). Matz et al. tested purified violacein and violacein producing biofilms with 
various protozoan species that includes flagellates, ciliates, and amoeba6. They showed that, when 
exposed to violacein, the bacteriovorous amoeba Acanthamoeba castellanii displays decreased feeding 
accompanied by morphological changes, such as cell rounding. Further observations, such as increases 
in caspase-3-like activity and TUNEL assay studies, suggest that these predacious microbes are dying 
via an apoptotic-like cell death33. 
In addition to its apparent roles in protecting the bacterium from predation, violacein seems to 
have other ecological functions that may provide advantages for the bacterium that produce it. For 
instance, violacein-producing Janthinobacterium forms biofilms and resides on the skins of frogs and 
salamanders26,34. In return, the violacein produced provides antifungal protection for their amphibian 
hosts, increasing their survival. 
 
1.5 Production of Violacein by Natural Host Strains 
Since violacein is produced naturally by many different strains, the use of these strains for its 
production seemed like a clear choice. However, many factors were found to influence the yields, 
including the agitation and aeration7, the inoculum size2,10 and the nutrients available2,10,35,36. 
One group applied response surface methodologies (RSM) to identify the best conditions to 
produce violacein with C. violaceum35. They initially analyzed 16 variables but eventually limited it to 
three – glucose, tryptone and yeast extract. While the latter two improved both the cell mass and 
violacein yields as they were increased, glucose was found to be negatively correlated with the violacein 
yields, and limiting its addition to the culture was advantageous. Using this technique, they were able 
to increase the dry cell mass from 7.5 to 21 g/L and the violacein yields from 170 to 430 mg/L with an 
extinction coefficient of 56.01 L/(g-cm). Although it is clear that the violacein yield was significantly 
improved, it should be noted that this does not represent a greater production of this bisindole by the 
bacterium on a per bacterium basis as the cell mass increased by 2.8-fold while the violacein increased 
by only 2.5-fold. Regardless, similar protocols could potentially be employed to raise the violacein 
yields on a per volume basis by optimizing the media preparations and growth conditions to increase 
the culture density. 
A more recent study using RSM with another violacein producing strain, Pseudoduganella sp. 
B2, previously Duganella sp. B2, found similar results as the concentration of beef extract used was a 
major impetus for violacein production2. They also identified the culture pH and the concentrations of 
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tryptophan and potassium nitrate as major players influencing the final violacein yields. The importance 
of tryptophan is not surprising as this is the precursor for violacein, while the impact of nitrate was 
thought to be related with nitrogen source availability for the growing bacterial cultures. Under the 
optimal conditions found, the authors claimed Duganella sp. B2 was capable of producing 1.6 g/l crude 
violacein, typically referring to the naturally produced mixture of violacein and deoxyviolacein. This 
value is under scrutiny, however, as the extinction coefficient used (10.955 L/(g-cm)) is far lower than 
that reported by other groups, which range from 10.955 to 74.3 L/(g-cm) in the literature2,35,37,38. 
However, the values reported A recent article by Rodrigues et al. (2013) highlighted the discrepancy 
caused by spectrophotometric-based determinations of violacein and deoxyviolacein concentrations and 
stated that this could result in violacein concentrations that are inflated by as much as 680%37. To 
address this in their study, therefore, Rodrigues et al. (2013) relied on HPLC measurements, which was 
actually proposed in an earlier study to be used in parallel with NMR, UV-Vis spectroscopy and mass 
spectroscopy when characterizing violacein and its production by bacterial strains38, not the extinction 
coefficients. Consequently, to avoid any potential confusion to the readers, this report will not list the 
published concentrations purified from fermentations unless they have been verified by HPLC. 
 
1.6 Production of Violacein within E. coli and Other Heterologous Hosts 
Since the genes required for the production of violacein are known to exist within a single 
operon, i.e., vioABCDE39, many groups have sought to clone and express these within other bacterial 
hosts, including E. coli8,37,39. The Pemberton group has focused on plasmid stability, an issue when 
trying to generate bacterial products long-term and in non-natural hosts. They found, for instance, when 
the violacein gene cluster was cloned into pHC79, a cosmid vector, that it was unstable and was lost in 
as much as 60% of the bacterial population when grown for 15 generations in the absence of antibiotic 
pressure40. They claimed that the same was true when they expressed the vioABCDE operon in a pUC18 
vector but were able to generate a stable construct using a broad host range IncP plasmid40,41. This 
plasmid, pPSX-Vio+, was stable without the need for antibiotics for more than 100 generations40, 
making it a potentially useful tool for the production of violacein. 
In a subsequent study, they found that the amount of violacein produced by E. coli was 
dependent upon the host, with E. coli strain JM109 producing 3.9-fold more violacein than E. coli strain 
DH5α when harboring the same plasmid41. The production of the alpha amylase protein, AmyA, from 
Streptomyces lividans was likewise found to be better in JM109 than DH5α, demonstrating that this 
phenotype was characteristic of JM109 and not due to the violacein genes. The authors attributed better 
results with JM109 to the genetic differences between the host strains but did not delve deeper into the 
mechanisms underlying this phenotype. However, they did identify a mutation within the plasmid which 
led to a further enhancement in the violacein yields41. This mutation, which the authors designated as 
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opv-1 (overproduction of violacein), results from the deletion of a single nucleotide within the region 
upstream of the vioA gene, leading to a 4.2 and 2.9-fold enhanced violacein yield from E. coli strains 
DH5α and JM109, respectively. 
A more recent study sought to engineer E. coli and its metabolic pathways to improve the 
violacein yields37. For this, the authors over-expressed the genes related with tryptophan production and 
knocked-out several genes and pathways which would detract the carbon flux away from this amino 
acid. The engineered E. coli strain, TRP11, produces about 
20 µmol tryptophan per gram dry cell weight. By comparison, the control wild-type strain only 
produced about 0.3 µmol Tryptophan/gDCW, representing an increase in the tryptophan concentration 
of more the 60-fold. They next introduced the vioD gene into the chromosome of this strain and a 
plasmid expressing the vioABCE genes. Performing fed-batch fermentations over a 12 day period with 
this strain, which they designated as Vio-4, they were able to generate 710 mg/L violacein at more than 
99% purity, demonstrating that E. coli can be used to produce high-level concentrations of this 
bisindoles specifically. E. coli, however, has not been the only strain to have been used as a host to 
produce the bisindole violacein. Both Citrobacter freundii and Enterobacter aerogenes have also been 
used with positive results42. 
 
1.7 Deoxyviolacein and Oxyviolacein 
Although violacein has received most of the attention, it is not the only compound being 
produced by the VioA, VioB, VioC, VioD and VioE proteins within these bacterial hosts. A recent article 
that describes the various products in detail was recently published and lists over a dozen different 
compounds that have been produced in tests with various strains, mutants and cell-free extracts13. 
Perhaps the best known derivative produced by the violacein biosynthetic pathway, however, is 
deoxyviolacein. In J. lividum, for example, deoxyviolacein (Figure 1.1) is also being produced, albeit 
at a lower level than violacein43. Similar results were also seen with Duganella sp. B2 where the HPLC 
peaks for deoxyviolacein were much smaller than those for violacein44. The percent deoxyviolacein 
within the crude violacein extracts obtained from the natural bacterial hosts is typically around 10 ~ 
20%, with the vast majority being violacein. This is also true for commercially available violacein from 
Sigma-Aldrich, which is prepared using J. lividum and certified as at least 85% violacein based upon 
HPLC analysis. 
Deoxyviolacein, which lacks a hydroxyl group (Figure 1.1), can be produced by omitting the 
VioD protein. Using a recombinant Citrobacter freundii carrying a plasmid with a knock-out in the vioD 
gene, a recent study by the Xing group reported on the high level production and characterization of 
deoxyviolacein44, with an emphasis given to the differences between violacein and deoxyviolacein. 
Their study showed, for example, that the photostability of deoxyviolacein was slightly better than 
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violacein in tests with either natural or UV light. Moreover, in 24 hour toxicity tests with HepG2 cell 
lines, violacein and deoxyviolacein were both found to be toxic. However, the impact of violacein was 
dose- dependent as greater additions of this bisindole led to greater concomitant losses in the HepG2 
viability. In contrast, the toxicity of deoxyviolacein was not dose-dependent but led to fairly consistent 
and stable losses in the viability over a range of concentrations (0.1 - 10µM). The difference between 
these two bisindoles was even more pronounced when the viability was determined after 48 hours. 
Several groups have also shown that the proteins responsible for the biosynthesis of violacein are not 
strict for their typical substrate, tryptophan, as 5-hydroxytryptophan can also be used to produce another 
derivative, oxyviolacein (Figure 1.1)45,46. In contrast with deoxyviolacein, which lacks a hydroxyl group 
when compared with violacein, oxyviolacein boasts an additional hydroxyl group. Likewise, as the loss 
of the hydroxyl group in deoxyviolacein reduced its efficacy against S. aureus, the presence of this extra 
hydroxyl group within oxyviolacein was found to increase the potency against this human pathogens47. 
 
1.8 Conclusions 
This review presents current research trends regarding the study and production of the 
bacterially-produced bisindole violacein and several derivatives. As a secondary metabolite, violacein 
has been found to possess a wide variety of biological activities, including anticancerous properties. 
These characteristics have led to renewed interest in this compound and its production by both wild-
type and recombinant bacterial strains. As presented in this report, the production and characterization 
of violacein is not without its own obstacles and struggles, and much work still needs to be done. This 
is particularly true regarding the mode of activity of violacein which needs to be studied more in depth. 
Current trends in molecular genetics are aiding in this as researchers are now capable of engineering 
bacterial host that can over-produce this bisindole within fermentations. As work with this compound 
and its derivatives progresses, it is anticipated that violacein will become more readily available for the 
scientific community and clinical studies. 
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Chapter 2. Isolation, Identification and Characterization of Violacein-Producing 
Pseudoduganella sp. NI28  
 
2.1 Summary  
A novel violacein-producing bacterial strain was isolated and identified as a relative of 
Pseudoduganella violaceinigra. However, this strain (designated P. sp. NI28) was found to be 
phenotypically very different from the type strain, P. violaceinigra YIM 31327. P. sp. NI28 grew 25% 
faster on nutrient media and produced 179-fold more violacein than P. violaceinigra YIM 31327. When 
compared with several other violacein producing strains, including Janthinobacterium lividum, P. sp. 
NI28 was the best violacein producer. Moreover, the violacein yield with P. sp. NI28 was 6.1 mg/OD 
at 24 hours, which is at least two-fold higher than all the other strains. P. violaceinigra YIM 31327 had 
the lowest yield (0.06 mg/OD). Finally, the antibacterial activity of P. sp. NI28 violacein was assayed 
using a clinical isolate of the pathogen Staphylococcus aureus. Violacein concentrations of 15, 30 and 
60 µM killed 78%, 96% and 99.5% of the initial S. aureus population, respectively.  
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2.2 Introduction 
Violacein is a bisindole derived from the condensation of two molecules of tryptophan48. This 
compound is vibrant purple in color and is known to possess a broad biological activity, including 
performing as an antitumor49, antifungal26 and antiviral50. Although not tested within humans to date, 
violacein has been found to have no adverse impact on mice when administered at a concentration of 1 
mg/kg49. It has recently garnered more attention, however, due to its antibacterial activity against 
Staphylococcus aureus32,51. Tests with this pathogen found that violacein is capable of both acting as a 
bacteriostatic and as a bacteriocidal agent against S. aureus depending on the concentration used22. 
Moreover, a recent study demonstrated that violacein works synergistically with other antibiotics, 
leading to significantly lower minimum inhibitory concentrations for S. aureus, Klebsiella pneumonia 
and Pseudomonas aeruginosa32. All three of these strains are included in the ESKAPE pathogen 
grouping, a list of multidrug resistant bacteria that are becoming more prominent within healthcare 
environments and nosocomial infections52,53. As such, research into the isolation and characterization 
of violacein producing bacteria, the cloning and heterogeneous expression of the vioABCDE genes and 
the fermentative production of violacein has recently blossomed with several key studies reported 
within the last couple of years37,42,44.  
Violacein is produced by numerous bacterial strains spanning various genera, including 
Chromobacter13,14, Pseudoalteromonas7,8,9, Janthinobacterium4,5 and Duganella2. Moreover, violacein 
producing bacterial strains have been isolated from diverse environmental locales. 
Janthinobacterium4,11,12, for instance, was isolated from a glacier, Chomobacteria from a river14, 
Duganella and Pseudoduganella from agricultural and forest soils10,24 and Collimonas from the sea1. In 
this study, we report on the isolation and initial characterization of a natural soil isolate, 
Pseudoduganella sp. NI28, obtained from a temperate forest soil sample taken near Ulsan, South Korea. 
This strain produces violacein at much higher rate and levels than the type strain Pseudoduganella 
violaceinigra YIM 3132724,54. The phenotypic differences between these two related strains help to 
illustrate the broad activity of violacein producing strains found in nature and their potential application 
within violacein research and production. 
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2.3 Materials and Methods 
2.3.1 Isolation of Pseudoduganella sp. NI28 
 The novel strain characterized in this study, i.e., Pseudoduganella sp. NI28, was isolated using 
soil obtained from a temperate forest nearby the campus. For this, a 50 g sample of soil was mixed with 
500 mL of sterile tap water and shaken at 30ºC for 2 hours. Afterwards, the soil particulates were 
centrifuged at 500 × g for 5 minutes and the supernatant sampled. Portions (100µl) of this solution were 
spread out on nutrient agar (NA) (1.6% agar; Difco, USA) plates, which were then incubated at 30ºC 
for 48 hours. A colony showing a violet hue was selected for further evaluation. 
 
2.3.2 Bacterial Strains and Growth 
The bacterial strains used in this study are listed in Table 2.1. All of the strains were grown 
from -80ºC freezer stocks that were prepared individually. For the violacein producing strains, the stocks 
were prepared by adding DMSO (Sigma-Aldrich, USA) to a final concentration of 10%. The 
Staphylococcus aureus strains were stored using glycerol (Sigma-Aldrich, USA) at a final concentration 
of 25%.  
Each violacein producing strain was struck out on NA plates and grown at 30ºC overnight. A 
single colony was transferred to a sterile 15 mL conical tube (SPL, Korea) containing 3 mL of nutrient 
broth (Difco, USA). This culture was grown at 30ºC and 250 rpm overnight. To 50 mL of fresh NB 
medium in a 100 mL baffled flask, 5 mL (10% v/v) of the overnight culture was added and this was 
again shaken at 30ºC and 250 rpm for 48 hours. At set times during this cultivation, 1 mL aliquots were 
taken for optical density determination. The S. aureus strains were grown using the same protocols 
except at 37ºC and in TSB media (Difco, USA). 
 
2.3.3 Identification of Pseudoduganella sp. NI28 by 16S using phylogenetic markers 
The genus of isolate NI28 was identified using three genes, namely 16S rRNA, gyrB and vioA. 
The primers for PCR amplification of the genes were 27f (5’-AGA GTT TGA TCM TGG CTC AG-3’) 
and 1492r (5’-GGT TAC CTT GTT ACG ACT T-3’) for the 16S rRNA gene, Up-1G (5’-YGC SGG 
CGG YAA GTT CGA-3’) and Up-2G (5’-CCR TCG ACG TCV GCR TCG GT-3’) for gyrB (Mavrodi 
et al. 2010), and VPA3 (5’-CCR CAG CTS CAY CCG CAT TTC CAG-3') and VPA4 (5’-CAG GCY 
GCC CTC CAT CCA GCC RCA-3’) for vioA (Hakvag et al. 2009). The PCR conditions for the gyrB 
gene were: 95ºC for 5 minutes followed by 35 cycles of 95ºC for 30 s, 60ºC for 15 s and 72ºC for 90 s. 
The final extension was at 72ºC for 5 minutes. The vioA gene was amplified in the same manner but 
with an annealing temperature of 62ºC. The phylogenetic analysis between NI28 and the related taxa  
12 
  
 
 
Table 2.1. Strains used in this study. 
 
Strains Description Referencea 
 Pseudoduganella sp. NI28  Violacein producer This study 
 Pseudoduganella violaceinigra  Violacein producer YIM 31327 
 Janthinobacterium lividum Violacein producer ATCC 12473 
 Chromobacterium pseudoviolaceum  Violacein producer ATCC 7461 
 Chromobacterium piscinae  Violacein producer LMG 3947 
 Chromobacterium subtsugae Violacein producer DSM 17043 
   
 Staphylococcus aureus Human pathogen ATCC 25923 
 Staphylococcus aureus Human pathogen Clinical Isolate 
a - YIM (Yunnan Institute of Microorganisms); ATCC (American Type Culture Collection); LMG 
(Belgian Coordinated Collection of Microorganisms); DSM (Deutsche SammLung von 
Mikroorganismen und Zellkulturen GmbH)  
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including Pseudoduganella was performed using MEGA 6.055. Neighbor-joining trees were inferred 
based on Jukes-Cantor evolutionary distances for each gene. The trees were evaluated using bootstrap 
analysis with 1,000 resampled datasets. The sequences of each gene from strain NI28 were deposited 
within the GenBank database under the accession numbers (KM087998, KM087999 and KM088000). 
 
2.3.4 Fatty Acid Methyl Ester Preparation and Analysis 
 Colonies of P. sp. NI28 and P. violaceinigra YIM 31327 grown on NA plates were used for 
this analysis. To prepare the samples, several colonies were transferred to a test tube and 1 mL of 
Reagent #1 (45 g NaOH (ACS Grade, Sigma-Aldrich, USA), 150 mL HPLC Grade methanol (Sigma-
Aldrich, USA) and 150 mL deionzed distilled water) was added. After vortexing to suspend the bacteria, 
this sample was placed at 100ºC for 5 minutes, vortexed once more and then incubated at 100ºC once 
more for 25 minutes. Afterwards, the tubes and samples were cooled down in a room temperature water 
bath. To initiate methylation of the fatty acids, 2 mL of Reagent #2 (325 mL 6 N HCl (Sigma-Aldrich, 
USA) mixed with 275 mL HPLC Grade methanol (Sigma-Aldrich, USA)) was added to each tube, 
which was vortexed and then incubated at 80ºC for 10 minutes. Afterwards, the tubes were quickly 
cooled by gently shaking them in a room temperature water bath. To each tube, 1.25 mL Reagent #3 
(prepared using an equal volume of HPLC Grade hexane (Sigma-Aldrich, USA) and HPLC Grade 
methyl tert-butyl ether (Sigma-Aldrich, USA)) was added and the contents were gently mixed end-over-
end for 10 minutes using a rotator. The aqueous phase was removed from the tubes and discarded. To 
remove any free fatty acids, the samples were washed with 3 mL of Reagent #4 (10.8 g ACS Grade 
sodium hydroxide in 900 mL deionized distilled water) by gently mixing them as above for 5 minutes. 
Once more, the aqueous phase was removed and discarded. The organic phase was used for gas 
chromatography (GC) analysis. For the GC analysis, the column was an Ultra 2 (25 m, 0.2 mm, Agilent, 
USA). The protocol used was the same as used previously for the Pseudoduganella violaceinigra type 
strain24. 
  
2.3.5 Phenotypic Assessment of P. sp. NI28 
 A comparative phenotypic analysis of P. sp. NI28 and YIM 31327 was performed using the 
API 20NE and API ZYM test kits (bioMerieux, France) according to the manufacturer’s suggested 
protocol.  
 
2.3.6 Extraction and HPLC Analysis of the Violacein Produced by P. sp. NI28 
 After growth for 0, 24 and 48 hours, 1 mL of the culture was pelleted by centrifugation for one 
minute at 16,200xg and room temperature. After aspirating off the media, the pellet was resuspended in 
an equal volume of ethanol and shaken at 37ºC and 250 rpm for 24 hours. Using this protocol, the 
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violacein present within the cells is extracted into the ethanol whereas pelleting of the bacterial cells 
afterwards found them to be completely extracted of violacein. The ethanol was then transferred to 
another centrifuge tube and the absorbance measured at 575 nm. This value was used to calculate the 
violacein concentration using an extinction coefficient of 73.4 L mg-1 cm-1 43. 
 The violacein sample was also analyzed using HPLC 1200 (Agilent, USA) as described 
previously43. For this, 10 µl samples of the ethanol extracted violacein were analyzed using a C-18 
column (Hypersil ODS, 5µm, 250 x 4.6 mm) at 30ºC. The mobile phase was 50% denatured ethanol 
(HPLC Grade, Sigma-Aldrich, USA) and detection was performed at 575 nm using an Agilent 1260 
Infinity ELSD. 
 
2.3.7 Standard curve of Commercial Violacein with HPLC and Spectrophotometry Analysis 
Using commercial violacein (Sigma-Aldrich, USA) violacein standard is measured by HPLC 
and Biochrom Libra S22 UV/Vis Spectrophotometer (Biochrom, USA) for helping quantification of 
violacein and detection limit checking with semi-micro cuvets (Ratiolab, Germany). Each violacein 
sample for standard curve is preferred 1, 2, 4, 6, 8 and 10mg/L concentration. The condition of HPLC 
analysis for standard curve is same as extracted violacein HPLC analysis. The spectrophotometry 
analysis was performed at 575nm wavelength. The violacein concentration within the ethanol extracts 
was determined as described above using violacein purchased from Sigma-Aldrich (USA, Cat. No. 
V9389) as a known standard. 
 
2.3.8 Violacein Killing of Staphylococcus aureus 
 The extracted violacein was concentrated by drying down multiple preparations under nitrogen 
gas and resuspending the violacein in DMSO. The concentration was once more determined as 
described above.  
 Two different strains of S. aureus (ATCC 25923 and a clinical isolate) were used to evaluate 
the activity of the violacein extracted from P. sp. NI28 cultures. After growth overnight, the S. aureus 
cultures were diluted 1:100 into 3 mL M9 modified minimal media containing 1 g/L tryptone and 0.2% 
glucose. Violacein (M.W. 343.33) was added to these cultures at a final concentration of 0, 15, 30 or 60 
µM. The cultures were then incubated at 37ºC and 250 rpm for 24 hours, after which the viable S. aureus 
numbers were determined using serial dilutions of the cultures that were spread out on TSB agar plates 
and grown overnight at 37ºC.  
 
2.3.9 Co-culture of violacein producing strain with Staphylococcus aureus 
 The independent culture of S. aureus ATCC 25923, J. lividum ATCC 12473, P. sp. NI28 and 
P. violaceinigra YIM 31327 was grown with NB 24hours. The 1% inoculum of S. aureus culture was 
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mixed with 20mL NB medium in the 100mL baffled flasks. After mixing with S. aureus culture in the 
four individual flasks, 2mL of 24 hours culture from J. lividum, P. violaceinigra and P. sp. NI28 was 
added in each flasks. The prepared J. lividum ∙ S. aureus, P. violaceinigra ∙ S. aureus, P. sp. NI28 ∙ S. 
aureus co-culture and S. aureus only culture was grown at 250RPM 30°C 24hours. After 24 hours, 
Optical density of culture and CFU analysis was performed for checking cell number and cell type 
identification, the violacein concentration in the co-culture was analyzed with spectrophotometer. 
 
2.3.10 Violacein Gene Cloning 
 The violacein gene was cloning by primer VPA3 and VPA4 what used for vioA sequencing, 
vioB, vioC and vioD were cloned by primer VioASeqF (5’ -CCCAAGCGGCA TCATCGCCTGC- 3’) 
and VioBSeqR (5’ -CGGTCGCACATCTGCCACATC- 3’) for vioB, VioBSeqF1 (5’ -
TTCGGCCTGGACACG GAATTTGC- 3’) and VioDSeqR(5’ –CACAGSGTSACGCCGGTGCTCAT- 
3’) for vioC, vioDNF (5’-AACATATGAAAATCCTCGTCATCGG-3’) and vioDXR (5’-
GTCCTCGAGGCGGCCGAGGGCGTAG C- 3’) for vioD cloning which primer was designed by 
homology region of J. agaricidamnosum, J. lividum, C. violaceum, Collimonas sp. and Duganella sp. 
violacein gene cluster in NCBI (National Center for Biotechnology Information) using MEGA 6. The 
PCR protocol was same referred above sequencing PCR, an annealing temperature of vioB was 63ºC, 
vioC was 69ºC. 
 
2.3.11 Data Analysis 
 Each of the experiments was performed in triplicate for error analysis. The standard deviations 
are presented as error bars in each graph where required. 
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2.4. Results  
2.4.1 Isolation and Identification of Pseudoduganella sp. NI28  
Various natural bacterial isolates from a forest soil sample were grown on nutrient agar (NA) 
and a single colony that had a dark purple hue, suggesting that this strain produced the bisindole 
violacein, was selected for further characterization. Production of violacein by this strain was 
demonstrated using HPLC analysis (Figure 2.1). When the violacein extracted from our new isolate was 
compared with a commercial preparation from Janthinobacterium lividum (Sigma-Aldrich, USA), they 
were basically indistinguishable from each other (retention time = 7.8 minutes). Moreover, 
deoxyviolacein was present in both samples (retention time = 11.3 minutes) but constituted only a minor 
fraction.  
Identification of this strain was next performed using the sequences obtained from three gene 
loci (16S rRNA, gyrB and vioA), with each confirming that it was closely related to Pseudoduganella 
violaceinigra YIM 31327 (Figures 2.2 and 2.3). The level of sequence similarities between NI28 and P. 
violaceinigra YIM 31327 were 98.8% for 16S rRNA gene, 95.9% for gyrB, and 88.8% for vioA, thus 
indicating that NI28 is close, but not identical to Pseudoduganella violaceinigra YIM 31327. This 
relationship was further supported by a fatty acid methyl ester (FAME) analysis and comparison of this 
strain and the type strain, Pseudoduganella violaceinigra YIM 31327, which showed only minor 
differences between the two strains (Table 2.2). Based upon the phylogenetic and FAME analyses, this 
strain was designated Pseudoduganella sp. NI28 and deposited within the Korea Agricultural Culture 
Collection (www.genebank.go.kr) (KACC 91951P).  
 
2.4.2 P. sp. NI28 is Phenotypically Variant from P. violaceinigra YIM 31327 
Although both Pseudoduganella sp. NI28 and P. violaceinigra YIM 31327 were isolated from 
forest soils and are related genetically based upon the above results, differences were readily apparent 
between them. For instance, P. sp. NI28 was found to have trypsin activity using the API ZYM Kit 
(bioMerieux, France) while P. violaceinigra YIM 31327 was negative for this protease. Furthermore, P. 
sp. NI28 grew remarkably well and produced a significant amount of violacein when cultured on NA 
(Figure 2.4A). This was in stark contrast with P. violaceinigra YIM 31327, which grew slower and was 
much less proficient at producing violacein. Figure 2.4A shows that colonies of P. sp. NI28 were larger 
and already producing violacein after 24 hours of growth while those of P. violaceinigra YIM 31327 
were smaller and still pasty in color. Only after 60 hours did the P. violaceinigra YIM 31327 colonies 
achieve a similar size and hue as 24 hour-old the P. sp. NI28 colonies (Figure 2.4A). Both of these 
findings were further evidenced in liquid cultures. As with the colonies, P. violaceinigra YIM 31327 
was slower to grow in NB liquid media  
Table 2.2. Fatty acid methyl ester (FAME) comparison between P. sp. NI28 and P. violaceinigra YIM  
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Figure 2.1. HPLC analysis of the violacein extracted from Pseudoduganella sp. NI28 cultures showing 
the predominant presence of violacein (7.9 min) and a small amount of deoxyviolacein (13.5 min). A 
plot generated using a commercially available violacein extracted from Janthinobacterium lividum is 
provided for comparison and illustrates the similarities between these two bacteria with regard to the 
violacein:deoxyviolacein ratio. 
Fatty Acid (%) NI28 YIM 31327 
Straight Chain   
   C10:0 - 0.4 
   C12:0 5.05 6.54 
   C14:0 2.99 1.04 
   C16:0 33.28 31.42 
Branched   
   Iso-C10:0 0.12 - 
Unsaturated   
   C14:1 - 0.26 
   C18:1 3.8 3.69 
Hydroxy   
   C10:0 - 3.82 
   C12:0 2.66 1.74 
   C14:0 3.41 3.6 
Sum in Feature 3a 48.68 47.49 
18 
  
 
 
Figure 2.2. Phylogenetic tree using the 16S rRNA gene sequence. The numbers at nodes indicate levels 
of bootstrap support (%) based on 1,000 resampled dataset. The bars corresponds to 0.01 or 0.05 
substitutions per nucleotide. In parentheses are the nucleotide sequence accession numbers of 
corresponding strains. 
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Figure 2.3. Phylogenetic trees using the (A) gyrB and (B) vioA gene sequences. The numbers at nodes 
indicate levels of bootstrap support (%) based on 1,000 resampled dataset. The bars corresponds to 0.01 
or 0.05 substitutions per nucleotide. In parentheses are the nucleotide sequence accession numbers of 
corresponding strains.  
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31327. (Figure 2.4B). The doubling time for P. violaceinigra YIM 31327 was 71 minutes based upon 
the logarithmic growth stage between 3 and 7 hours. In contrast, P. sp. NI28 doubled every 53.7 minutes, 
a value that is 25 % faster than P. violaceinigra YIM 31327. Not only did the newly isolated P. sp. NI28 
grow faster but the final optical density was significantly higher (1.7-fold), as shown in Figures 2.4B 
and 2.5A. We also noticed that P. sp. NI28 tended to form flocs when grown in liquid cultures while P. 
violaceinigra YIM 31327 cells generally remained suspended (data not shown). It is not clear what 
benefit P. sp. NI28 gains from forming these aggregates, but it was reported that flocs may help protect 
against predation56.  
 
2.4.3 Pseudoduganella sp. NI28 is a Prolific Violacein Producer  
All three of these growth characteristics (rate, yield and floc formation) may contribute to the 
higher violacein production seen with this new strain. As shown in Figure 2.5B, Pseudoduganella sp. 
NI28 was a much more proficient violacein producer than P. violaceinigra YIM 31327 under these 
conditions, generating as much as 14.6 mg/L after 24 hours. Further incubation for an additional 24 
hours did not improve upon this yield. P. violaceinigra YIM 31327, on the other hand, produced 0.08 
mg/L during the first 24 hours, which is 179-fold less than P. sp. NI28, and reached only 0.2 mg/L after 
48 hours (74-fold less).  
 Although Pseudoduganella sp. NI28 is clearly better than P. violaceinigra YIM 31327 at 
producing violacein, the literature also lists several other violacein producing strains, including 
Chromobacter species and Janthinobacterium lividum (Table 2.1). Consequently, we cultivated each of 
these strains in NB media and determined both the optical density (OD) and violacein yields after 24 
and 48 hours (Figure 2.5). When compared with these other violacein producing strains, P. sp. NI28 
growth in NB was not much better, with both C. piscinae and C. subtsugae growing to much higher 
ODs (Figure 2.5A). However, of all the strains tested, the new isolate was the best violacein producer, 
particularly when grown for 24 hours (Figure 2.5B). This figure also shows that it was one of only two 
strains that reached a maximum violacein concentration in 24 hours. This rapid and high level 
production by P. sp. NI28 in NB clearly sets this strain apart from the other strains, particularly its 
closest relative, P. violaceinigra YIM 31327, which was the poorest violacein producer tested in this 
study. 
When the quantity of violacein produced by all six strains was normalized using the OD, the 
newly isolated P. sp. NI28 gave the best results (Figure 2.5C). This was particularly true for the 24 hour 
sample where the yield was 6.1 mg violacein/OD, a value that was more than twice that obtained for 
the next closest strain, C. piscinae (2.9 mg violacein/OD). The type strain P. violaceinigra YIM 31327 
was by far the worst producer with respect to violacein yield (0.06 and 0.19 mg/OD at 24 and 48 hours, 
respectively). P. sp. NI28’s high level production of violacein implies that this strain contains more  
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Figure 2.4. P. sp. NI28 grows faster than P. violaceinigra YIM 31327. (A) Image of each strain grown 
on NB agar plates for 24 and 60 hours. The upper and bottom regions are from the same plate. Note the 
more rapid colony development and violacein production by P. sp. NI28. (B) Growth of both strains in 
NB media confirming that P. sp. NI28 grows faster. The data for each strain was obtained from three 
independent cultures. 
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Figure 2.5. Growth and violacein production by several different bacterial strains. (A) Optical density 
values for each culture at 0, 24 and 48 hours. (B) Violacein concentration within each culture at the 
same time points, showing the rapid and high level violacein generation by P. sp. NI28 as compared 
with the other strains. (C) The relative concentration of violacein based upon the culture density, 
illustrating that P. sp. NI28 gave the greatest yields.  
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violacein per cell than the other strains, a finding which may contribute to making downstream 
purification of violacein easier. 
 
2.4.4 Standard Curve of Commercial Violacein with Spectrophotometry and HPLC Analysis 
 Almost every study of violacein contained measurement of violacein with various method, 
spectrophotometry is one kinds of established measurement technique which used several recent 
articles2, 35,38,43. However, the extinction coefficient for spectrophotometry is not equal every different 
papers. The standard curve of spectrophotometry analysis is shown figure 2.6A. The measured 
extinction coefficient of commercial violacein is 68.4 L mg-1 cm-1. The purity of commercial violacein 
is not 100%, measured extinction coefficient is very similar with Rodrigues et al. (2012) which value 
considered its purity. 
 HPLC analysis for quantification of pure violacein inside crude violacein is performed with 
commercial violacein which contain small amount of deoxyviolacein (Figure 2.6B) Thus only violacein 
peak integration value is calculated for HPLC standard curve. In this reason the violacein amount in 
standard curve is lower estimated compared than pure violacein. The limitation of HPLC analysis 
integration is around 80ng of violacein.  
 
2.4.5 Pseudoduganella sp. NI28 Violacein is Bacteriocidal Towards Staphylococcus aureus 
 Several recent articles highlighted the activity of violacein against the human pathogen 
Staphylococcus aureus and showed that a concentration of 17 µM was capable of inhibiting growth of 
this strain32,51. Similarly, we tested the activity of P. sp. NI28 violacein extracts with two S. aureus 
isolates that were obtained from a culture repository (ATCC 25923) and from a patient infected with a 
multidrug-resistant S. aureus (Clinical). As shown in Figure 2.7, the violacein prepared from P. sp. NI28 
was capable of blocking growth of both S. aureus strains when added to a final concentration of 15 µM. 
Moreover, this concentration led to a 70% loss in viability after 24 hours when compared with the initial 
S. aureus colony-forming unit (CFU) values while higher concentrations led to comparably greater 
losses in viability. For instance, 60 µM violacein reduced both S. aureus populations by an average of 
99.5% when compared with the initial CFU numbers.  
 The co-culture results significantly indicate the cidal effect of violacein in the culture. Figure 
2.8 shown co-culture of violacein producing strain with S.aureus ATCC25923. The optical density of 
co-culture is increased both of Pseudoduganella species in figure 2.8A, rather than J. lividum co-culture. 
J.lvidum and NI28 produce violacein almost similar amount at single culture and co-culture presented 
figure 2.5B and figure 2.8B. The interesting point to distinguish violacein producing strain or not in the 
viability of S. aureus and P. violaceinigra after co-culture. P. violaceinigra was genetically similar to 
NI28, however, viability difference with N28 with co-culture of S. aureus is significantly different;   
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Figure 2.6. Standard curve of commercial violacein with spectrophotometry (A) and HPLC (B) analysis. 
The extinction coefficient is 68.4 L mg-1 cm-1. Integration data is shown high linearity in 1 to 8mg/L 
concentration range, over 10mg/L the value of integration is decreased in 10μL injection. 
A) 
B) 
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Figure 2.7. Inhibition and killing of Staphylococcus aureus by P. sp. NI28 violacein. Two S. aureus 
strains were tested: ATCC 25923 and a clinical isolate. The initial CFU was determined just prior to 
addition of the violacein. The viability of the other samples was determined after a 24 hour exposure to 
the violacein at the concentrations listed, showing that the addition of 15 µM or greater violacein was 
bactericidal towards both pathogenic strains.  
  
26 
  
 
 
 
 
 
 
Figure 2.8. Co-culture of violacein producing strain with S. aureus ATCC 25923 after 24hours. (A) 
Single culture and co-culture of S. aureus with J. lividum ATCC 12473, P. violaceinigra YIM 31327 
and P. sp. NI28 in NB media. The single culture was measured for comparison of co-culture. (B) 
Violacein produced amount in the cell of J. lividum and NI28. P. violaceinigra doesn’t produced 
violacein in this condition. (C) CFU counts of violacein producing strain from co-culture inoculum. The 
colonies of P.violaceinigra is not found. (D) CFU counts of S.aureus from co-culture inoculum. The 
colonies of S. aureus in the co-cultured with violacein produced strain.  
  
A) B) 
C) D) 
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NI28 is survived within co-culture, P. violaceinigara is not (figure 2.8C). Moreover S. aureus viability 
with the violacein producing strains is also dropped dynamically (figure 2.8D).  
 
2.4.6 Pseudoduganella sp. NI28 violacein gene cluster sequencing  
 The violacein gene cluster was sequenced around 70%. The vioA partial sequence is uploaded 
in the NCBI (KM087998). Figure 2.9 is the sequence of Pseudoduganella sp. NI28 violacein gene 
cluster which already done. 
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Figure 2.9. Scheme of sequenced region of Pseudoduganella sp. NI28 compare than Duganella sp. 
ZLP-XI strains violacein gene cluster. Image captured from the NCBI BLAST analyses showing the 
regions within the P. sp. NI28 vioABCDE operon that have been sequenced. The sequences obtained 
were BLASTed against the Duganella sp. ZLP-XI violacein biosynthesis gene cluster, which 
consistently showed some of the best homology to P. sp. NI28. The bottom image shows the location 
of the various genes within the sequences and was obtained using the NEB Cutter v. 2.0 program 
available online. 
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2.5 Discussion 
As a bacterial secondary metabolite, violacein has been garnering renewed interest lately. A 
vibrant violet-hued bisindole derivative of tryptophan, violacein has been shown to have multiple 
biological activities, including as an anticancer and antibiotic, particularly against S. aureus. It is this 
multifaceted character of violacein, and the fact that resistance to this antibiotic has not yet been 
described, that makes it an attractive product for bioprocesses. 
This study reports on the isolation and characterization of a novel high-level violacein-
producing bacterial strain. This strain was identified as Pseudoduganella using both FAME and 
phylogenetic analyses and found to be similar based upon these tests with P. violaceinigra YIM 31327, 
which is regarded as the type strain for this genus and also produces violacein. However, when these 
two strains were compared with each other, we found P. sp.NI28 was quite distinct from P. violaceinigra 
YIM 31327 in several attributes. For instance, the new strain grew much faster and produced 
significantly more violacein (179-fold) than P. violaceinigra YIM 31327. Although the exact reasons 
for the differences between these closely related strains is not clear, the rapid and high level production 
of violacein by P. sp. NI28 and its tendency to form flocs, another attribute that is only seen with P. sp. 
NI28 and has been noted as being more economical when harvesting microbial biomass57, make it an 
attractive strain for the commercial production of violacein. 
Consequently, we compared its violacein production and yield with four additional strains, 
including J. lividum and C. piscinae. Once more, P. sp. NI28 had the fastest production rates and highest 
yields. The benefits of this strain were most evident at 24 hours, which is when it achieved its maximum 
violacein concentration. This concentration was 2.3-fold higher than that obtained by the next closest 
strain, C. piscinae, and was still higher than the violacein concentrations achieved by any of the strains 
even after an additional 24 hours of cultivation. Moreover, the amount of violacein produced per cell, 
as based upon the optical density (OD), was highest with P. sp. NI28. Once more, C. piscinae was the 
closest contender but the violacein per OD with this culture was still 2.1-fold lower than with P. sp. 
NI28. Even after 48 hours, P. sp. NI28 remained the best strain based upon the violacein per OD. Both 
the rapid, high-level production by P. sp. NI28 and its higher concentration within the cells are clearly 
advantageous and desirable from an economic viewpoint since they reduce the time needed for 
production of violacein as well as minimize the biomass needed for its subsequent extraction and 
purification. 
When the violacein from P. sp. NI28 cultures was purified and analyzed, we found that its 
purity was similar with a commercially available preparation from J. lividum. As noted above, this 
bisindole is quite effective against S. aureus and, as such, experiments were performed using the P. sp. 
NI28 preparation. For this, the effects of different concentrations of violacein on an S. aureus strain 
obtained from the American Type and Culture Collection (ATCC) as well as a clinical isolate were 
30 
  
 
 
tested. The results show that both strains were severely inhibited and killed by the P. sp. NI28 
preparation (Figure 2.7). Previous studies stated that the minimal inhibitory concentration of violacein 
with S. aureus was a concentration of 5.7 µg/mL, or approximately 17 mM32. The preparation from P. 
sp. NI28, when using a slightly lower concentration, was not only inhibitory but actually led to a 
significant loss in S. aureus viability. When compared with the initial CFU numbers, a 24-hour treatment 
with 5 µg/mL, or approximately 15 mM, led to a 69% reduction in the viability with the ATCC strain 
and a 78% decrease with the clinical isolate. Although it is not clear why the preparation in this study 
appears to be more potent, the data clearly illustrates that the violacein purified from cultures of P. sp. 
NI28 is capable of not only inhibiting S. aureus growth but also killing this pathogen. On the other hand 
co-culture of violacein producing strains with S. aureus has significant benefit to violacein producing 
viability. In co-culture viability checking by CFU test, most of S. aureus lose their viability with the 
violacein producing strain, P. violaceinigra co-culute is not, even genotype of NI28 and P. violaceinigra 
is very similar. That shows violacein producing is affect to S.aureus growth not only violacein in the 
media but also in the cell. Therefore, there is possibility that improved violacein production of NI28 
than type strains help the competition between gram positive strains and violacein producing strains. 
In conclusion, a novel violacein-producing strain was isolated from a forest soil sample in 
Ulsan, South Korea. This strain, P. sp. NI28, produces violacein at quicker and at higher levels than 
other comparable strains, particularly the type strain P. violaceinigra YIM 31327. Although the 
concentrations produced in this study are low, a group recently reported achieving as much as 0.82 g/L 
with C. violaceum by optimizing the conditions for fermentation and the media used23. As P. sp. NI28 
was generally better than the other strains tested in this study, expanding its growth and violacein 
production through similar techniques would likely increase the yields. Moreover, other recent studies 
have shown the successful expression of the vioABCDE operon within other bacterial hosts to produce 
even higher levels of violacein. The characteristics of P. sp. NI28 make its vioABCDE operon an 
interesting addition to these studies and, as such, cloning of these genes may likewise be beneficial. 
Moreover, the violacein extract is active towards the human pathogen S. aureus, showing bactericidal 
effects at all the concentrations tested. As such, P. sp. NI28 is an attractive strain for the production of 
violacein and for further study, particularly the cloning, sequencing and heterologous expression of its 
vioABCDE genes. 
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Chapter 3. Fermentative Production of Deoxyviolacein and Construction of Its 
Producing Strain from Improved L-Tryptophan synthesis pathway Escherichia 
coli 
 
3.1 Summary 
Violacein and deoxyviolacein are components of crude violacein from several strains such as 
J.lividum, C.violaceum, Duganella sp., Pseudoduganella sp., Collimonas sp. The usage of violacein in 
the bio-application field is various and sub-divided, needs of amount of violacein and its derivation will 
be increase. Nevertheless this outlook, the production of the violacein is not established well than 
biofuel field. In this reason, we make the crude violacein production strain, GPT vio, from modification 
of L-tryptophan producing E.coli strain called GPT1002. BBa J72214 BBa J72090, the violacein 
production plasmid containing the vioABCDE gene which known 5 major gene for production of 
violacein, is inserted in GPT 1002 strain with electroporation. Fermentation using GPT vio in the 
superbroth with 1g/L of L-tryptophan, is shown that production of crude violacein reach the around 
501.8mg/L after 24h fermentation and its purity, measured by HPLC, is deoxyviolacein 95% over. The 
production rate per unit time is 20.91mg/L·h and 1.65 times enhanced rate recently reported 
12.66mg/L·h. Moreover the temperature of fermentation is always 37°C that is improved cell growth 
and violacein production rate without low temperature or temperature switching. 
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3.2 Introduction 
Violacein and its derivation made by two indole from tryptophan side chain. These insoluble 
compounds has violet color in visible ray, violacein maximum absorbance is shown 210nm and 575nm 
wavelength with UV-Vis spectrum and its derivation can detectable similar wavelength range with 
HPLC.38 This chemicals has several biotic effect to various organism like gram-positive bacteria58,15, 
virus38, fungus59, protozoan27,60 and nematode.29 Following recent study, several cancer cell line like 
Hep250, KM1233, MOLT-433 and other cell lines have a cytotoxicity when violacein was 
treated.61,62,63,64,65 Moreover Staphylococcus aureus which has multidrug resistance is also influenced 
the violacein51, other study demonstrated Salmonella typhi, Vibrio cholera, Klebsiella pneumonia and 
Pseudomonas aeruginosa is also affected by violacein, on the other hand it help other antibiotics affect 
to these organism.32 
Nevertheless this numerous virtue and positive point to application, violacein study is not 
activated because of two significant problem; their production amount and not established measurement 
methods. Recent study of production of violacein is optimization of natural violacein producing strain 
culture, recombinant violacein production is not activate. For instance, violacein production of 
recombinant Escherichia coli vio-4 strain is shown highest final concentration (0.7g/L) and high purity 
of violacein production (98%>), however, specific productivity of violacein is 3.1mg/L∙h37, that is 1/4 
of optimized crude violacein production Chromobacterium violaceum.15 Moreover measurement 
methods are not unified, different research group use different measurement and standard. Even early 
stage of violacein production, this confusing standard is delayed violacein production study and its 
application.  
In this study, we improved specific deoxyviolacein production for pre-stage of violacein 
production using tryptophan overproducing E.coli strains and recombinant plasmid for converting 
deoxyviolacein to violacein production. Most of violacein measurement is following spectrophotometer 
and HPLC method recently published. 
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3.3 Material and Methods 
3.3.1 Transformation of violacein production strain 
Violacein is well known to bisindole molecule which need tryptophan for their precursor. That 
means metabolic engineering point of view, accumulation of tryptophan directly help violacein 
production, so tryptophan overproducing strain E.coli GPT1002 is used in this experiment.66 GPT 1002 
is transformed with plasmid BBa J72214 BBa J72090 (addgene plasmid) and plasmid pCOM10 vio.42 
GPT1002 with BBa J72214 BBa J72090 is named GPTvio and GPT1002 with pCOM10vio named GPT 
pCOM10vio. Transfomation was performed by electroporation which use 1800V with 10% glycerol 
washed competent cells. Time constant of purse for electroporation is average 5.4 sec. (table 3.1) To 
screening of this recombinant strain, appropriate antibiotics is chosen; chloramphenicol 35μl/mL, 
kanamycin 50μl/mL and spectinomycin 100μl/mL. 
 
3.3.2 Microbial production extract and purification of crude violacein 
 For extraction of violacein recombinant E.coli GPTvio and GPT pCOM10vio was grown in 
LB media 250RPM and 37°C for 24hours. 1% initial inoculum is used for second culture for violacein 
production of GPT vio violacein production. For GPT pCOM10vio violacein production is need 25°C, 
so second culture is performed this temperature. Each inoculum volume of culture media is 20mL in 
100mL baffled flask for enhance oxygen concentration inside.  
 Extraction of violacein was completed by ethanol extraction which is well known for violacein 
production.38 The 1mL inoculum was pelleted using centrifuge in one minute and 16200xg in room 
temperature condition. After draining supernatant from pellet, pellet was washed several times by 1mL 
of ethanol by resuspension before pellet color change white or bright gray. The ethanol solution that 
used washing of pellet was gathered.  
 
3.3.3 Violacein quantification and purity measurement with HPLC 
 The violacein sample from culture was analyzed by HPLC 1200 (Agilent, USA) according to 
Rodrigues, et al. 43 Sample was preferred by optical density around 0.50 in 575nm wave length. Each 
sampling injection 10μl, ethanol extract was analyzed with a C-18 (Hypersil ODS, 5µm, 250 x 4.6 mm) 
at 30ºC. 50% denatured ethanol (HPLC Grade, Sigma-Aldrich, USA) was used for the mobile phase 
and 575 nm detection was performed with Agilent 1260 Infinity ELSD. 
   
3.3.4 Recombinant plasmid for converting violacein production  
 The crude violacein that extracted from GPT vio consisted of deoxyviolacein, additional 
plasmid is need for converting deoxyviolacein to violacein production. The converting of this process 
is need expression of vioD gene in the deoxyviolacein producing strain.67 The pCOM10vio plasmid 
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shown vioD working in the recombinant E.coli, vioD is purified from this plasmid. For vioD purification 
primer vio3046-for and vioE-rev (Table 3.2) were used for PCR.42 After purification vioD contained 
DNA fragment was amplified designed primer vioDFH, vioDRB pair and vioDNF, vioDXR pair. (Table 
3.2) For making pUC19 vioD plasmid, vioDFH-vioDRB primer vioD fragments, restriction enzyme for 
pUC19 vioD BamH I and Hindi III fast digest, T4 ligase (Thermo Scientific, USA) was used. In case 
of pET31b+ vioD plasmid, vioDNF-vioDXR fragments, Nde I and Xho I(Thermo Scientific, USA). 
After construct of pUC19 vioD and pET31b+ vioD, E.coli DH5α vio (BBa J72214 BBa J72090) was 
transformed with pUC19 vioD or pET31b+ vioD by electroporation.  
 
3.3.5 Violacein derivation fermentation 
 GPT vio and GPT pCOM10vio is used fermentation of violacein derivation. For a lab scale 
fermentation, 3L bioreactor (Fermentech, Korea) is used for violacein producing. 12h cultured 
recombinant E. coli is first inoculum in LB 37°C, 250RPM, 100mL culture volume, 250mL flask 
without baffled. In 3L fermenter, super broth (35g/L tryptone, 20g/L yeast extract, NaCl 5g/L, 5M 
sodium hydroxide 1mL/L) with 10%(v/v) is preferred for fermentation. The condition of fermentation 
is 500RPM, pH 7.2 ± 0.4, 1.5vvm, total volume 1L. pH was maintained by 1M HCl and 25% NH4OH 
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Table 3.1. Strains and plasmid used in this study. 
 
Strains Description Reference 
 Escherichia coli W3110  Wild type 68,69 
Escherichia coli DH5α Wild type 70 
Escherichia coli BL21 Wild type 71 
 Escherichia coli GPT1002 Tryptophan over producer 66 
 Escherichia coli W3110 vio Violacein producer This study 
 Escherichia coli W3110 pCOM10vio  Violacein producer This study 
 Escherichia coli GPT vio  Violacein producer This study 
 Escherichia coli GPT pCOM10vio Violacein producer This study 
Escherichia coli DH5α vioD Violacein producer with vioD This study 
 Escherichia coli BL21 vioD Violacein producer with vioD This study 
Plasmids Resistance Description Reference 
 pTAT SpcR Tryptophan over producer 66 
 BBa J72214 BBa J72090 CamR Violacein producer Addgene, USA 
 pCOM10 vio KanR Violacein producer 42 
 pUC19 AmpR Vector 72 
 pET31b+ AmpR Vector 73 
 pUC19 vioD AmpR vioD plasmid This study 
 pET31b+ vioD AmpR vioD plasmid This study 
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Table 3.2. Primer used in this study 
 
Primers Sequence 
vio3046-for 5′- TACATGACTCAGGTCGAAGCGGCCGCCAAG -3′ 
 vioE-rev 5′- GGAATGTCCTCGAGTTCCGACACGAAAACGCTGGC -3′ 
 vioDFH 5’- AAGAAGCTTAACGTTTGGTACAAACTTGG -3’ 
 vioDRB 5’- GGTGGATCCGCGTCTCCTTAGCGGCCG -3’ 
 vioDNF 5’- AACATATGAAAATCCTCGTCATCGG -3’ 
 vioDXR 5’- GTCCTCGAGGCGGCCGAGGGCGTAGC -3’ 
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3.4 Results and discussions 
3.4.1 Recombinant strain violacein production strain 
 Figure 3.1 is schematic of GPT vio and GPT pCOM10vio and its morphology. Transformed 
violacein producing strain GPT vio which is prepared by plasmid BBa J72214 BBa J72090 is shown 
that the colony was black colored because of crude violacein production. GPT pCOM10vio strain grown 
in 37 °C is general E. coli morphology but after violacein production in 25°C, colony color is changed 
dark purple after 24 hours. 
 
3.4.2 Fermentation of crude violacein production with GPT vio and GPT pCOM10vio 
 Fermentative production of violacein is shown figure 3.2A. GPT pCOM10vio is produce low 
violacein production even addition n-octane. Even violacein production is delayed because of low 
temperature condition for violacein production of pCOM10 vio need 25°C. Final crude violacein 
concentration produced by GPT pCOM10vio is ~12mg/L, specific productivity of 0.24 mg/L∙h which 
is pretty low specific productivity. GPT vio crude violacein production amount is presented figure 3.2B. 
Crude violacein production under 37 °C is touching 501.9mg/L in 24h. Specific productivity of crude 
violacein production of GPT vio is 20.91 mg/L∙h. The cell growth of those two different strain GPT 
pCOM10 vio and GPT vio fermentation reached 19.6 and 29.0 within 48hours. 
Batch fermentation for crude violacein production is stuck because several reason like lack of 
tryptophan source for making violacein, deficiency of energy for making violacein, stack of waist in 
the media. These data is suggest high cell density cultivation is commonly helped growth of violacein 
producing strain, production of violacein is increasing follow the cell growth and it stopped when these 
strain reached the stationary phase. Other substantial point of crude violacein over production is pH 
affect to the media. When violacein production is quick in action, pH of media contained violacein 
producing strain is shown increasing tendency. Therefore violacein production has positive correlation 
with pH rising that caused extra amino acid from tryptophan metabolism. The production of crude 
violacein from GPT vio was detected >95% deoxyviolacein by HPLC analysis which performed rater, 
the deoxyviolacein production amount 501.9mg/L within 24 hours (20.91mg/L∙h) is 1.65 folds higher 
specific productivity compare than recently reported deoxyviolacein production 950mg/L within 
75hours (12.66mg/L∙h) 74. The final concentration of deoxyviolacein from GPT vio is 584.8 mg after 
72h in batch culture. 
 
3.4.3 HPLC purity analysis of crude violacein from GPT vio and pCOM10 vio 
 The crude violacein purity is not analyzed in several recent study, however, for identification 
of purity of crude violacein, HPLC analysis should be preceded. Figure 3.3 is the HPLC data represent 
three peaks; first peak is the mobile phase 50% ethanol, second peak is violacein, deoxyviolacein is last 
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Figure 3.1. Picture of recombinant E. coli strain for crude violacein production. (A) E. coil GPT vio 
strain in 37°C 24 hours culture. The colony color is turned to black in 37°C incubator. (B) E. coil GPT 
pCOM10vio strain in 37°C 24 hours and 25°C 24 hours culture. The color of colony is transference dim 
yellow in 37°C incubator. When 25°C culture, the colony color is turned to dark violet. 
  
A) 
B) 
39 
  
 
 
 
 
 
Figure 3.2. Fermentation of crude violacein form recombinant violacein producing strain. Amount of 
violacein and deoxyviolacein was calculated using HPLC43. (A) GPT pCOM10vio fermentation. GPT 
pCOM10vio produced violacein based upon HPLC analysis, amount of violacein is re-calculated after 
HPLC analysis (B) GPT vio crude violacein fermentation. Following the HPLC data, GPT vio produce 
only deoxyviolacein. The amount of deoxyviolacein was measured by spectrophotometer.37, 43 
 
  
A) 
B) 
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Figure 3.3. HPLC analysis with extracted crude violacein from GPT vio and GPTpCOM10vio compare 
with commercial violacein (Sigma-Aldrich, USA). Crude violacein from GPT vio is only represent two 
peaks. GPT pCOM10vio and Commercial violacein have independent peaks after 2min from first peak 
come. 
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peak following previous HPLC study.43 
Violacein originated J. lividum which sold commercially and extracted from natural isolated 
Psedoduganella sp. NI28 is indicate dominant of violacein in natural producing. The violacein peak of 
GPT pCOM10vio was epitomized that low concentration production of violacein inside recombinant E. 
coli strain is similar pattern of natural violacein production. Nevertheless this possibility of high purity 
violacein production inside recombinant strain shown GPT pCOM10 vio, crude violacein production 
of GPT vio is biased deoxyviolacein. Figure 3.4 is scheme of violacein production pathway. In violacein 
producing pathway, deoxyviolacein bypass producing is happened by low expression level expression 
or functional problem of vioD tryptophan hydroxylase inside vioABCDE gene complex.67 Thus 
unexpected deoxyviolacein production can be fixed by vioD expression control. 
 
3.4.4 vioD gene cloning and its crude violacein HPLC analysis 
 The vioD from BBa J72214 BBa J72090 has possibility of vioD expression problem. To 
eliminate this option, vioD is purified from pCOM10vio which produce high concentration of violacein 
analyzed by HPLC. Following this cloning, possibility of vioD enzyme functional problem caused by 
gene itself is eliminated. Figure 3.5 is HPLC analysis of DH5α vioD and BL21 vioD. Both of the strains 
has dual plasmid which forced by two different antibiotics to maintain its plasmid. Even cloning of vioD 
gene, both of crude violacein producing strain make not violacein but deoxyviolacein. 
Nevertheless fastidious condition reenact of pCOM10vio violacein production to avoid vioD 
denaturation in various temperature. Deoxyviolacein production is not shifted to violacein. That means, 
vioD expression is not only problem of this unexpected production bypath, other unpredictable reason 
affect to vioD gene or VioD enzyme itself. 
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Figure 3.4. Scheme of violacein production pathway from tryptophan with vioABCDE enzyme. The 
structures were prepared using ChemDoodle 2D sketcher (http://web.chemdoodle.com/demos/sketcher). 
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Figure 3.5. HPLC analysis of DH5α vioD and BL21 vioD recombinant strain extracted violacein 
compare with commercial violacein (Sigma-Aldrich, USA). Commercial violacein has two peak after 
elution phase peak shown. All recombinant strain shown deoxyviolacein peak above figure. 
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3.5 Conclusion 
 This study treat the violacein production inside recombinant E. coli and its unexpected side 
effect of this experiment. The violacein itself is very powerful chemical defined various field like 
anticancer, antiprotozoan, antivius, antibacterial. In this reason violacein production will be supported 
to mass production convert by its application. One of attractive point of violacein production is easy to 
establish, because of the production is only need five continuous gene and its expression with 
tryptophan. So violacein production is necessary referred reason. 
 In this study, we clone the violacein producing gene to E. coli using tryptophan accumulating 
violacein to help violacein production and we make high crude violacein production strain. HPLC 
analysis of the crude violacein is indicate most of this violacein derivation consist of deoxyviolacein. 
Measured deoxyviolacein final concentration is 501.9mg/L in 24h, specific productivity of 
deoxyviolacein is 20.91mg/L that is 1.65 fold high value to compare than already known. The problem 
of this bypath production of violacein is not solved. Even vioD gene from other high purity violacein 
produced sample is cloned to violacein. 
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Chapter 4. Concluding Remarks 
 
4.1 Summary and Conclusions 
 This study focus on the violacein and its application with antibiotic effect and its production. 
As started in chapter 1, the violacein is versatile pigment made by several bacteria strains such as 
Chromobacter, Janthinobacterium, Pseudoaltermonas, Colilimonas sp, Duganella sp and 
Pseudoduganella sp that was found from glacier to subtropical region. This diverse violacein producing 
host in the various climate suggest violacein production has benefit in the nature condition. The 
researcher estimate production of the violacein has relative dominant to fight their natural competitor 
like gram positive bacteria, fungus and protozoan.  
 In this purpose, the natural violacein producing host called Pseudoduganella sp. NI28 is 
isolated in chapter 2. In the study of two different type strain Pseudoduganella violaceinigra YIM 
31327 and isolated strain P. sp. NI28, the phenotype and genotype of this two strain shown some 
similarity. The growth curve, FAME study, colonies morphology represent very small phenotype 
difference between two strains, gene sequence of 16s rRNA, gyrB and vioA shown 98.8%, 95.9% and 
88.8% similarity. That indicate NI28 and type strains is close but not same species. So this difference 
well shown higher violacein specific productivity in same condition compare than type strain, 
additionally other violacein producing host like Chromobacter sp and J. lividum which is very well-
known violacein producer.  
 The extracted violacein is shown S. aureus cidal effect which tested by S. aureus with certain 
concentration of violacein. In 60 μM of violacein shown 99.5% of S. aureus is killed by violacein 
compare than initial number of cell even S. aureus clinical isolated or not. Moreover co-culture of 
violacein strain with S. aureus shown violacein production killed S. aureus even though it is in the cell 
not the media. In this reason, it is suggested that violacein is powerful tools to against S. aureus which 
make issue of in-hospital infection cause of multi drug resistance.  
Consequently, the focus of study move to the point to production of violacein to secure the 
amount of violacein. For increase violacein production, NI28 violacein gene cluster is sequenced with 
primer design at the end of chapter 2, however, it is not complete. Thus recombinant strain 
transformation was performed with violacein producing plasmid already constructed from other group 
in chapter 3. The recombinant E. coli GPT vio is shown high deoxyviolacein productivity, the final 
concentration is around 584.8mg after 3 days, fastest specific productivity is 20.91mg/L∙h within 
24hours. That is highest deoxyviolacein production and productivity recent study. However 
deoxyviolacein is not violacein but product of vioABCE gene working, that means vioD expression or 
enzyme activity has problem. To overcome this problem, a plasmid that contain vioD gene is constructed 
and inserted to other recombinant E.coli. Still all of recombinant strain shown deoxyviolacein 
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production. 
 
4.2 Further study 
This study present the isolation and characterization of violacein producing stain 
Pseudoduganella sp. NI28 and the production of deoxyviolacein by recombinant E. coli strains. The 
characterization of violacein producing strain suggest that Pseudodugnaella sp. NI28 is different to type 
strain and it shown high productivity than other strain, the production of deoxyviolacein reached the 
highest productivity compare than recent study. 
Nevertheless this achievement, the violacein gene cluster of NI28 which has possibility to 
increase the productivity of violacein, is not sequenced completely. So recombinant E. coli GPT vio is 
not use NI28 violacein gene but other constructed violacein plasmid. On the other hand, deoxyviolacein 
production of GPT vio strains is not expected. The deoxyviolacein is derivation of violacein but it is 
not violacein. To overcome this problem, vioD plasmid is constructed and transformed to other strains, 
DH5α vioD and BL21 vioD strain however, both of strains didn’t produce the violacein.  
Therefore studies of violacein gene cluster Pseudoduganella sp. NI28 sequencing and cloning 
is should be performed. Moreover recombinant strains using that gene cluster should be constructed for 
enhance violacein productivity. On the one hand, vioD gene activity problem will be studied to solve 
deoxyviolacein production instead of violacein in the recombinant E. coli strains for further studies. 
 
 
  
47 
  
 
 
REFERENCES 
 
1. Hakvag, S.; Fjaervik, E.; Klinkenberg, G.; Borgos, S. E. F.; Josefsen, K. D.; Ellingsen, T. E.; 
Zotchev, S. B., Violacein-Producing Collimonas sp from the Sea Surface Microlayer of Costal 
Waters in Trondelag, Norway. Mar Drugs 2009, 7 (4), 576-588. 
2. Wang, H. S.; Jiang, P. X.; Lu, Y.; Ruan, Z. Y.; Jiang, R. B.; Xing, X. H.; Lou, K.; Wei, D., 
Optimization of culture conditions for violacein production by a new strain of Duganella sp 
B2. Biochem Eng J 2009, 44 (2-3), 119-124. 
3. Jude, B. A.; Tanner, J.; Koko, T.; McLaughlin, E. C., Analysis, characterization, and synthesis 
of violacein from Janthinobacterium isolate extracts. Abstr Pap Am Chem S 2012, 244. 
4. Lu, Y.; Wang, L. Y.; Xue, Y.; Zhang, C.; Xing, X. H.; Lou, K.; Zhang, Z. D.; Li, Y.; Zhang, G. 
F.; Bi, J. X.; Su, Z. G., Production of violet pigment by a newly isolated psychrotrophic 
bacterium from a glacier in Xinjiang, China. Biochem Eng J 2009, 43 (2), 135-141. 
5. Pantanella, F.; Berlutti, F.; Passariello, C.; Sarli, S.; Morea, C.; Schippa, S., Violacein and 
biofilm production in Janthinobacterium lividum. J Appl Microbiol 2007, 102 (4), 992-999. 
6. Matz, C.; Webb, J. S.; Schupp, P. J.; Phang, S. Y.; Penesyan, A.; Egan, S.; Steinberg, P.; 
Kjelleberg, S., Marine Biofilm Bacteria Evade Eukaryotic Predation by Targeted Chemical 
Defense. Plos One 2008, 3 (7). 
7. Yang, L. H.; Xiong, H.; Lee, O. O.; Qi, S. H.; Qian, P. Y., Effect of agitation on violacein 
production in Pseudoalteromonas luteoviolacea isolated from a marine sponge. Lett Appl 
Microbiol 2007, 44 (6), 625-630. 
8. Zhang, X.; Enomoto, K., Characterization of a gene cluster and its putative promoter region 
for violacein biosynthesis in Pseudoalteromonas sp 520P1. Appl Microbiol Biot 2011, 90 (6), 
1963-1971. 
9. Mccarthy, S. A.; Johnson, R. M.; Kakimoto, D.; Sakata, T., Effects of Various Agents on the 
Pigment (Violacein) and Antibiotic Production of Alteromonas-Luteoviolacea. B Jpn Soc Sci 
Fish 1985, 51 (7), 1115-1121. 
10. Aranda, S.; Montes-Borrego, M.; Landa, B. B., Purple-Pigmented Violacein-Producing 
Duganella spp. Inhabit the Rhizosphere of Wild and Cultivated Olives in Southern Spain. 
Microb Ecol 2011, 62 (2), 446-459. 
11. Avgustin, J. A.; Bertok, D. Z.; Kostanjsek, R.; Avgustin, G., Isolation and characterization of 
a novel violacein-like pigment producing psychrotrophic bacterial species Janthinobacterium 
svalbardensis sp nov. Anton Leeuw Int J G 2013, 103 (4), 763-769. 
12. Kim, S. J.; Shin, S. C.; Hong, S. G.; Lee, Y. M.; Lee, H.; Lee, J.; Choi, I. G.; Park, H., Genome 
Sequence of Janthinobacterium sp Strain PAMC 25724, Isolated from Alpine Glacier 
48 
  
 
 
Cryoconite. J Bacteriol 2012, 194 (8), 2096-2096. 
13. Hoshino, T., Violacein and related tryptophan metabolites produced by Chromobacterium 
violaceum: biosynthetic mechanism and pathway for construction of violacein core. Appl 
Microbiol Biot 2011, 91 (6), 1463-1475. 
14. Moss, M. O.; Ryall, C.; Logan, N. A., Classification and Characterization of Chromobacteria 
from a Lowland River. J Gen Microbiol 1978, 105 (Mar), 11-21. 
15. Duran, N.; Menck, C. F. M., Chromobacterium violaceum: A review of pharmacological and 
industiral perspectives. Crit Rev Microbiol 2001, 27 (3), 201-222. 
16. McClean, K. H.; Winson, M. K.; Fish, L.; Taylor, A.; Chhabra, S. R.; Camara, M.; Daykin, 
M.; Lamb, J. H.; Swift, S.; Bycroft, B. W.; Stewart, G. S. A. B.; Williams, P., Quorum sensing 
and Chromobacterium violaceum: exploitation of violacein production and inhibition for the 
detection of N-acylhomoserine lactones. Microbiol-Uk 1997, 143, 3703-3711. 
17. Burt, S. A.; Ojo-Fakunle, V. T. A.; Woertman, J.; Veldhuizen, E. J. A., The Natural 
Antimicrobial Carvacrol Inhibits Quorum Sensing in Chromobacterium violaceum and 
Reduces Bacterial Biofilm Formation at Sub-Lethal Concentrations. Plos One 2014, 9 (4). 
18. Rajesh, P. S.; Rai, V. R., Quorum quenching activity in cell-free lysate of endophytic bacteria 
isolated from Pterocarpus santalinus Linn., and its effect on quorum sensing regulated biofilm 
in Pseudornonas aeruginosa PAO1. Microbiol Res 2014, 169 (7-8), 561-569. 
19. Taganna, J. C.; Quanico, J. P.; Perono, R. M. G.; Amor, E. C.; Rivera, W. L., Tannin-rich 
fraction from Terminalia catappa inhibits quorum sensing (QS) in Chromobacterium 
violaceum and the QS-controlled biofilm maturation and LasA staphylolytic activity in 
Pseudomonas aeruginosa. J Ethnopharmacol 2011, 134 (3), 865-871. 
20. Duran, M.; Faljoni-Alario, A.; Duran, N., Chromobacterium violaceum and its important 
metabolites - review. Folia Microbiol 2010, 55 (6), 535-547. 
21. Lichstein, H. C.; Vandesand, V. F., Violacein, an Antibiotic Pigment Produced by 
Chromobacterium-Violaceum. J Infect Dis 1945, 76 (1), 47-51. 
22. Nakamura, Y.; Sawada, T.; Morita, Y.; Tamiya, E., Isolation of a psychrotrophic bacterium 
from the organic residue of a water tank keeping rainbow trout and antibacterial effect of 
violet pigment produced from the strain. Biochem Eng J 2002, 12 (1), 79-86. 
23. Ahmad, W. A.; Yusof, N. Z.; Nordin, N.; Zakaria, Z. A.; Rezali, M. F., Production and 
Characterization of Violacein by Locally Isolated Chromobacterium violaceum Grown in 
Agricultural Wastes. Appl Biochem Biotech 2012, 167 (5), 1220-1234. 
24. Li, W. J.; Zhang, Y. Q.; Park, D. J.; Li, C. T.; Xu, L. H.; Kim, C. J.; Jiang, C. L., Duganella 
violaceinigra sp nov., a novel mesophilic bacterium isolated from forest soil. Int J Syst Evol 
Micr 2004, 54, 1811-1814. 
49 
  
 
 
25. Yada, S.; Wang, Y.; Zou, Y.; Nagasaki, K.; Hosokawa, K.; Osaka, I.; Arakawa, R.; Enomoto, 
K., Isolation and characterization of two groups of novel marine bacteria producing violacein. 
Mar Biotechnol 2008, 10 (2), 128-132. 
26. Brucker, R. M.; Harris, R. N.; Schwantes, C. R.; Gallaher, T. N.; Flaherty, D. C.; Lam, B. A.; 
Minbiole, K. P. C., Amphibian Chemical Defense: Antifungal Metabolites of the 
Microsymbiont Janthinobacterium lividum on the Salamander Plethodon cinereus. J Chem 
Ecol 2008, 34 (11), 1422-1429. 
27. Leon, L. L.; Miranda, C. C.; De Souza, A. O.; Duran, N., Antileishmanial activity of the 
violacein extracted from Chromobacterium violaceum. J Antimicrob Chemoth 2001, 48 (3), 
449-450. 
28. Lopes, S. C. P.; Blanco, Y. C.; Justo, G. Z.; Nogueira, P. A.; Rodrigues, F. L. S.; Goelnitz, U.; 
Wunderlich, G.; Facchini, G.; Brocchi, M.; Duran, N.; Costa, F. T. M., Violacein Extracted 
from Chromobacterium violaceum Inhibits Plasmodium Growth In Vitro and In Vivo. 
Antimicrob Agents Ch 2009, 53 (5), 2149-2152. 
29. Hornung, C.; Poehlein, A.; Haack, F. S.; Schmidt, M.; Dierking, K.; Pohlen, A.; Schulenburg, 
H.; Blokesch, M.; Plener, L.; Jung, K.; Bonge, A.; Krohn-Molt, I.; Utpatel, C.; Timmermann, 
G.; Spieck, E.; Pommerening-Roser, A.; Bode, E.; Bode, H. B.; Daniel, R.; Schmeisser, C.; 
Streit, W. R., The Janthinobacterium sp HH01 Genome Encodes a Homologue of the V. 
cholerae CqsA and L. pneumophila LqsA Autoinducer Synthases. Plos One 2013, 8 (2). 
30. Nakamura, Y.; Asada, C.; Sawada, T., Production of antibacterial violet pigment by 
psychrotropic bacterium RT102 strain. Biotechnol Bioproc E 2003, 8 (1), 37-40. 
31. Vynne, N. G.; Mansson, M.; Gram, L., Gene Sequence Based Clustering Assists in 
Dereplication of Pseudoalteromonas luteoviolacea Strains with Identical Inhibitory Activity 
and Antibiotic Production. Mar Drugs 2012, 10 (8), 1729-1740. 
32. Subramaniam, S.; Ravi, V.; Sivasubramanian, A., Synergistic antimicrobial profiling of 
violacein with commercial antibiotics against pathogenic micro-organisms. Pharm Biol 2014, 
52 (1), 86-90. 
33. Melo, P. D.; Maria, S. S.; Vidal, B. D.; Haun, M.; Duran, N., Violacein cytotoxicity and 
induction of apoptosis in V79 cells. In Vitro Cell Dev-An 2000, 36 (8), 539-543. 
34. Harris, R. N.; Brucker, R. M.; Walke, J. B.; Becker, M. H.; Schwantes, C. R.; Flaherty, D. C.; 
Lam, B. A.; Woodhams, D. C.; Briggs, C. J.; Vredenburg, V. T.; Minbiole, K. P. C., Skin 
microbes on frogs prevent morbidity and mortality caused by a lethal skin fungus. Isme J 
2009, 3 (7), 818-824. 
35. Mendes, A. S.; de Carvalho, J. E.; Duarte, M. C. T.; Duran, N.; Bruns, R. E., Factorial design 
and response surface optimization of crude violacein for Chromobacterium violaceumi 
50 
  
 
 
production. Biotechnol Lett 2001, 23 (23), 1963-1969. 
36. Riveros, R.; Haun, M.; Duran, N., Effect of Growth-Conditions on Production of Violacein 
by Chromobacterium-Violaceum (Bb-78 Strain). Braz J Med Biol Res 1989, 22 (5), 569-577. 
37. Rodrigues, A. L.; Trachtmann, N.; Becker, J.; Lohanatha, A. F.; Blotenberg, J.; Bolten, C. J.; 
Korneli, C.; Lima, A. O. D.; Porto, L. M.; Sprenger, G. A.; Wittmann, C., Systems metabolic 
engineering of Escherichia coli for production of the antitumor drugs violacein and 
deoxyviolacein. Metab Eng 2013, 20, 29-41. 
38. Rettori, D.; Duran, N., Production, extraction and purification of violacein: an antibiotic 
pigment produced by Chromobacterium violaceum. World J Microb Biot 1998, 14 (5), 685-
688. 
39. August, P. R.; Grossman, T. H.; Minor, C.; Draper, M. P.; MacNeil, I. A.; Pemberton, J. M.; 
Call, K. M.; Holt, D.; Osburne, M. S., Sequence analysis and functional characterization of 
the violacein biosynthetic pathway from Chromobacterium violaceum. J Mol Microb Biotech 
2000, 2 (4), 513-519. 
40. Sarovich, D. S.; Pemberton, J. M., pPSX: A novel vector for the cloning and heterologous 
expression of antitumor antibiotic gene clusters. Plasmid 2007, 57 (3), 306-313. 
41. Ahmetagic, A.; Pemberton, J. M., Stable high level expression of the violacein 
indolocarbazole anti-tumour gene cluster and the Streptomyces lividans amyA gene in E. coli 
K12. Plasmid 2010, 63 (2), 79-85. 
42. Jiang, P. X.; Wang, H. S.; Zhang, C.; Lou, K.; Xing, X. H., Reconstruction of the violacein 
biosynthetic pathway from Duganella sp B2 in different heterologous hosts. Appl Microbiol 
Biot 2010, 86 (4), 1077-1088. 
43. Rodrigues, A. L.; Gocke, Y.; Bolten, C.; Brock, N. L.; Dickschat, J. S.; Wittmann, C., 
Microbial production of the drugs violacein and deoxyviolacein: analytical development and 
strain comparison. Biotechnol Lett 2012, 34 (4), 717-720. 
44. Jiang, P. X.; Wang, H. S.; Xiao, S.; Fang, M. Y.; Zhang, R. P.; He, S. Y.; Lou, K.; Xing, X. H., 
Pathway redesign for deoxyviolacein biosynthesis in Citrobacter freundii and characterization 
of this pigment. Appl Microbiol Biot 2012, 94 (6), 1521-1532. 
45. Sanchez, C.; Brana, A. F.; Mendez, C.; Salas, J. A., Reevaluation of the violacein biosynthetic 
pathway and its relationship to indolocarbazole biosynthesis. Chembiochem 2006, 7 (8), 
1231-1240. 
46. Hoshino, T.; Ogasawara, N., Studies on the Biosynthesis of Violacein .3. Biosynthesis of 
Violacein - Evidence for the Intermediacy of 5-Hydroxy-L-Tryptophan and the Structure of 
a New Pigment, Oxyviolacein, Produced by the Metabolism of 5-Hydroxytryptophan. Agr 
Biol Chem Tokyo 1990, 54 (9), 2339-2346. 
51 
  
 
 
47. Wang, H. S.; Wang, F. Z.; Zhu, X. F.; Yan, Y. C.; Yu, X. H.; Jiang, P. X.; Xing, X. H., 
Biosynthesis and characterization of violacein, deoxyviolaceiri and oxyviolacein in 
heterologous host, and their antimicrobial activities. Biochem Eng J 2012, 67, 148-155. 
48. Hoshino, T.; Kondo, T.; Uchiyama, T.; Ogasawara, N., Studies on the Biosynthesis of 
Violacein .1. Biosynthesis of Violacein - a Novel Rearrangement in Tryptophan-Metabolism 
with a 1,2-Shift of the Indole Ring. Agr Biol Chem Tokyo 1987, 51 (3), 965-968. 
49. Bromberg, N.; Dreyfuss, J. L.; Regatieri, C. V.; Palladino, M. V.; Duran, N.; Nader, H. B.; 
Haun, M.; Justo, G. Z., Growth inhibition and pro-apoptotic activity of violacein in Ehrlich 
ascites tumor. Chem-Biol Interact 2010, 186 (1), 43-52. 
50. Andrighetti-Frohner, C. R.; Antonio, R. V.; Creczynski-Pasa, T. B.; Barardi, C. R. M.; Simoes, 
C. M. O., Cytotoxicity and potential antiviral evaluation of violacein produced by 
Chromobacterium violaceum. Mem I Oswaldo Cruz 2003, 98 (6), 843-848. 
51. Cazoto, L. L.; Martins, D.; Ribeiro, M. G.; Duran, N.; Nakazato, G., Antibacterial activity of 
violacein against Staphylococcus aureus isolated from Bovine Mastitis. J Antibiot 2011, 64 
(5), 395-397. 
52. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, 
M.; Spellberg, B.; Bartlett, J., Bad Bugs, No Drugs: No ESKAPE! An Update from the 
Infectious Diseases Society of America. Clin Infect Dis 2009, 48 (1), 1-12. 
53. Sanji, N.; Dinakar, K. R.; Bilal, S. M.; Vishwanath, G.; Somashekar, H. S.; Pavani, S., 
Antibiotic Sensitivity of the E. Coli, Staph. Aureus, Klebsiella, Acinetobacter, Pseudomonas 
and Enterococci (Eskape) Organisms Isolated From the Endotracheal Tubes From Intensive 
Care Units of a Tertiary Care Hospital. Indian J Pharmacol 2013, 45, S194-S195. 
54. Kampfer, P.; Wellner, S.; Lohse, K.; Martin, K.; Lodders, N., Duganella phyllosphaerae sp 
nov., isolated from the leaf surface of Trifolium repens and proposal to reclassify Duganella 
violaceinigra into a novel genus as Pseudoduganella violceinigra gen. nov., comb. nov. Syst 
Appl Microbiol 2012, 35 (1), 19-23. 
55. Tamura, K.; Stecher, G.; Peterson, D.; Filipski, A.; Kumar, S., MEGA6: Molecular 
Evolutionary Genetics Analysis Version 6.0. Mol Biol Evol 2013, 30 (12), 2725-2729. 
56. Hahn, M. W.; Hofle, M. G., Flagellate predation on a bacterial model community: Interplay 
of size-selective grazing, specific bacterial cell size, and bacterial community composition. 
Appl Environ Microb 1999, 65 (11), 4863-4872. 
57. Vandamme, D.; Foubert, I.; Muylaert, K., Flocculation as a low-cost method for harvesting 
microalgae for bulk biomass production. Trends Biotechnol 2013, 31 (4), 233-239. 
58. Duran, N.; Erazo, S.; Campos, V., Bacterial Chemistry-Ii - Anti-Microbial Photoproduct from 
Pigment of Chromobacterium-Violaceum. An Acad Bras Cienc 1983, 55 (3), 231-234. 
52 
  
 
 
59. Shirata, A.; Tsukamoto, T.; Yasui, H.; Hata, T.; Hayasaka, S.; Kojima, A.; Kato, H., Isolation 
of bacteria producing bluish-purple pigment and use for dyeing. Jarq-Jpn Agr Res Q 2000, 
34 (2), 131-140. 
60. Matz, C.; Deines, P.; Boenigk, J.; Arndt, H.; Eberl, L.; Kjelleberg, S.; Jurgens, K., Impact of 
violacein-producing bacteria on survival and feeding of bacterivorous nanoflagellates. Appl 
Environ Microb 2004, 70 (3), 1593-1599. 
61. Saraiva, V. S.; Marshall, J. C.; Cools-Lartigue, J.; Burnier, M. N., Cytotoxic effects of 
violacein in human uveal melanoma cell lines. Melanoma Res 2004, 14 (5), 421-424. 
62. de Carvalho, D. D.; Costa, F. T. M.; Duran, N.; Haun, M., Cytotoxic activity of violacein in 
human colon cancer cells. Toxicol in Vitro 2006, 20 (8), 1514-1521. 
63. Kodach, L. L.; Bos, C. L.; Duran, N.; Peppelenbosch, M. P.; Ferreira, C. V.; Hardwick, J. C. 
H., Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and 
inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 
2006, 27 (3), 508-516. 
64. Queiroz, K. C. S.; Milani, R.; Ruela-de-Sousa, R. R.; Fuhler, G. M.; Justo, G. Z.; Zambuzzi, 
W. F.; Duran, N.; Diks, S. H.; Spek, C. A.; Ferreira, C. V.; Peppelenbosch, M. P., Violacein 
Induces Death of Resistant Leukaemia Cells via Kinome Reprogramming, Endoplasmic 
Reticulum Stress and Golgi Apparatus Collapse. Plos One 2012, 7 (10). 
65. Ferreira, C. V.; Bos, C. L.; Versteeg, H. H.; Justo, G. Z.; Duran, N.; Peppelenbosch, M. P., 
Molecular mechanism of violacein-mediated human leukemia cell death. Blood 2004, 104 (5), 
1459-1464. 
66. Gu, P. F.; Yang, F.; Kang, J. H.; Wang, Q.; Qi, Q. S., One-step of tryptophan attenuator 
inactivation and promoter swapping to improve the production of L-tryptophan in Escherichia 
coli. Microb Cell Fact 2012, 11. 
67. Hirano, S.; Asamizu, S.; Onaka, H.; Shiro, Y.; Nagano, S., Crystal structure of VioE, a key 
player in the construction of the molecular skeleton of violacein. J Biol Chem 2008, 283 (10), 
6459-6466. 
68. Bachmann, B. J., Pedigrees of Some Mutant Strains of Escherichia-Coli K-12. Bacteriol Rev 
1972, 36 (4), 525-557. 
69. Jensen, K. F., The Escherichia-Coli K-12 Wild Types W3110 and Mg1655 Have and Rph 
Frameshift Mutation That Leads to Pyrimidine Starvation Due to Low Pyre Expression Levels. 
J Bacteriol 1993, 175 (11), 3401-3407. 
70. Taylor, R. G.; Walker, D. C.; Mcinnes, R. R., Escherichia-Coli Host Strains Significantly 
Affect the Quality of Small-Scale Plasmid DNA Preparations Used for Sequencing. Nucleic 
Acids Res 1993, 21 (7), 1677-1678. 
53 
  
 
 
71. Daegelen, P.; Studier, F. W.; Lenski, R. E.; Cure, S.; Kim, J. F., Tracing Ancestors and 
Relatives of Escherichia coli B, and the Derivation of B Strains REL606 and BL21(DE3). J 
Mol Biol 2009, 394 (4), 634-643. 
72. Yanischperron, C.; Vieira, J.; Messing, J., Improved M13 Phage Cloning Vectors and Host 
Strains - Nucleotide-Sequences of the M13mp18 and Puc19 Vectors. Gene 1985, 33 (1), 103-
119. 
73. Kuliopulos, A.; Walsh, C. T., Production, Purification, and Cleavage of Tandem Repeats of 
Recombinant Peptides. J Am Chem Soc 1994, 116 (11), 4599-4607. 
74. Rodrigues, A. L.; Becker, J.; Lima, A. O. D. S.; Porto, L. M.; Wittmann, C., Systems 
Metabolic Engineering of Escherichia Coli for Gram Scale Production of the Antitumor Drug 
Deoxyviolacein From Glycerol. Biotechnol Bioeng 2014, 111 (11), 2280-2289. 
 
  
54 
  
 
 
Acknowledgements 
 불확신과 불안감, 두려움으로 시작한 석사를 끝내며 이런 어리숙한 저를 도와주
신 많은 분들께 먼저 감사를 전하고 싶습니다. 먼저, 철없는 사내의 허황된 말에도 꿈을 
가진 녀석이라며 이 길을 가도록 도와주신 지도교수님 Robert J. Mitchell께 감사를 드립
니다. 바쁘신 와중에도 저의 연구를 도와주시고 또한 논문심사에도 참석해주신 이성국 
교수님과 이진일 교수님께 감사의 말씀을 드립니다. 또한 제 연구생활에 도움을 주신 김
철민 교수님, 이진형 박사님, 윤경혜 박사님께도 깊은 감사의 말씀을 드립니다. 
연구실 생활과 연구자의 소양을 쌓게 도와주신 시선 누나, 형이자 후배인 껄끄러
운 관계에도 늘 본보기가 되었던 한솔이, 매번 잔 실수를 고치도록 지적해주었던 현수, 
실험 외의 부분에 문제가 없도록 도와주신 아람 선생님, Mohammed gave lots of help 
and advice, Ajay taught the many experimental technique, Sandrine, 다른 학부 학생 친구
들 까지 모두 고맙습니다. 
 석사생활을 무사히 끝마치도록 도와준 형과 어머니, 항상 사랑합니다. 마지막으
로 서로의 본보기가 되었던 다른 연구자 친구들, 저의 버팀목이 되어주었던 소중한 모든 
사람들에게 감사를 전하고 싶습니다.  
